Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
Oncology Letters
Join Editorial Board Propose a Special Issue
Print ISSN: 1792-1074 Online ISSN: 1792-1082
Journal Cover
August-2017 Volume 14 Issue 2

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
August-2017 Volume 14 Issue 2

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article Open Access

Inactivated Wnt signaling in resveratrol-treated epidermal squamous cancer cells and its biological implication

  • Authors:
    • Zhi‑Li Liu
    • Hong Li
    • Jia Liu
    • Mo‑Li Wu
    • Xiao‑Yan Chen
    • Li‑Hong Liu
    • Qian Wang
  • View Affiliations / Copyright

    Affiliations: Liaoning Laboratory of Cancer Genomics and Department of Cell Biology, Dalian Medical University, Dalian, Liaoning 116044, P.R. China
    Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
  • Pages: 2239-2243
    |
    Published online on: June 22, 2017
       https://doi.org/10.3892/ol.2017.6458
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

Squamous cell carcinoma (SCC) is the most common epidermal malignancy, and Wnt/β‑catenin signaling is frequently activated in SCC. Resveratrol prevents rodent epidermal carcinogenesis, while its effect on human epidermal cancer remains unknown. To address this issue, the impact of resveratrol on the growth and Wnt signaling of skin SCC Colo16 cells were investigated at the cellular and molecular biology levels by flow cytometry, immunocytochemistry, reverse transcription‑polymerase chain reaction, western blotting and β‑catenin‑specific small interfering RNA (siRNA) transfection. Resveratrol (100 µM) suppressed cell growth and induced apoptosis in Colo16 cells. Wnt2 and its downstream genes were downregulated, which was accompanied by increased expression of the Wnt signaling inhibitor Axin2. Transfection with a β‑catenin‑specific siRNA did not affect cell growth but enhanced the resveratrol susceptibility of Colo16 transfectants. The present results suggest the inhibitory effects of resveratrol on epidermal SCCs and inactivation of Wnt signaling as one of the resveratrol‑caused molecular events in Colo16 cells. β‑catenin oriented siRNA is insufficient to induce cell crisis, implicating the presence of more critical cancer‑associated element(s) as the target in Colo16 cells.

Introduction

Squamous cell carcinoma (SCC) is the most common skin malignancy, with aggressive behavior and poor prognosis at the advanced stage. Surgery remains the first choice of SCC treatment, but the highly invasive tendency and chemoresistance to local therapy of SCC cells usually lead to in situ occurrence and distal dissemination (1). Therefore, exploring a better adjuvant therapy for advanced skin SCCs would improve patients' life quality and survival rates.

Resveratrol possesses a wide range of biological activities, including cancer preventive and therapeutic effects (2). Previous studies performed on rodent models revealed that resveratrol regulated apoptosis and cell survival in mouse skin tumors (3), and exerted chemopreventive effects against ultraviolet-B exposure-mediated damages in SKH-1 hairless mouse skin (4). Nevertheless, the impact of resveratrol on human epidermal SCCs has been less described. The current study therefore aims to investigate i) the biological effects of resveratrol on human epidermal SCC cells; ii) the status of Wnt signaling in resveratrol-treated cells; and iii) the response of normally cultured and resveratrol-treated Colo16 cells when Wnt signal transduction is specifically suppressed by β-catenin-specific small interfering RNA (siRNA).

Materials and methods

Cells and treatment

Colo16 human cutaneous SCC cells were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum (both Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) at 37°C in 5% CO2 (5). Resveratrol (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) was dissolved in dimethylsulfoxide (DMSO) and diluted with culture medium to 100 µM just prior to use. The treatments lasted for 72 h, and the cells were collected in 24-h intervals for different experimental purposes. Normally cultured cells and cells cultured in medium containing 0.2% DMSO were used as controls. The experiments were repeated ≥3 times to establish a reliable conclusion.

Cellular and molecular examinations

Hematoxylin and eosin (H&E) morphological staining and immunocytochemical (ICC) staining for Ki-67 (sc-23900; Santa Cruz, Biotechnology, Inc., Dallas, TX, USA), Wnt2 (sc-514382; Santa Cruz Biotechnology, Inc.), Wnt5a (sc-365376; Santa Cruz Biotechnology, Inc.), β-catenin (sc-7963; Santa CruzBiotechnology, Inc.), cyclin D1 (sc-8396; Santa Cruz Biotechnology, Inc.), c-Myc (sc-40; Santa Cruz Biotechnology, Inc.), vascular endothelial growth factor (VEGF; sc-7269; Santa Cruz Biotechnology, Inc.), surviving (sc-17779; Santa Cruz, Biotechnology, Inc.) and Axin2 (BS7417; Bioworld Technology, Inc., St Louis Park, MN, USA) were performed on cell-bearing coverslips by methods described elsewhere (6,7). The proliferation activity and death pattern of resveratrol-treated Colo16 cells were further analyzed by flow cytometry (BD Biosciences, San Jose, CA, USA) and terminal deoxynucleotidyl transferase dUTP nick-end labeling colorimetric apoptotic cell assay (Promega Corporation, Madison, WI, USA), as previously described (7). The cell viability was determined after treatment for 24 or 48 h with different concentrations of resveratrol using an MTT assay as previously described (7). The results are presented as the percentage of cell viability [optical density (OD) of the experiment samples/OD of the control] or OD values. The 50% inhibitory concentration (IC50) value was statistically analyzed by SPSS version 15.0 (SPSS, Inc., Chicago, IL, USA). RNA and protein samples were prepared from the experimental groups and subjected to reverse transcription-polymerase chain reaction (RT-PCR) and western blot analyses for the same parameters evaluated by ICC staining (Table I)(6,8).

Table I.

The primer sequences for reverse transcription-quantitative polymerase chain reaction.

Table I.

The primer sequences for reverse transcription-quantitative polymerase chain reaction.

GenePrimersAmplicon Size (bp)Annealing temperature (°C)
Wnt2F: 5′-GCCACACGCTGCACCTAAAGC-3′
R: 5′-CAATTACCCTAAGGGTGGTAGC-3′37963
Wnt5aF: 5′-CTAACTTAGCTGTGTGGGACATG-3′
R: 5′-AAATGCAGAAAGCAAGCTAGCAG-3′25460
Axin2F: 5′-GGTGTTTGAGGAGATCTGGG-3′
R: 5′-TGCTCACAGCCAAGACAGTT-3′15358
SurvivinF: 5′-GGCATGGGTGCCCCGACGTTG-3′
R: 5′-CAGAGGCCTCAATCCATGGCA-3′43958
c-mycF: 5′-TGGTCTTCCCCTACCCTCTCAAC-3′
R: 5′-GATCCAGACTCTGACCTTTTGCC-3′26556
Cyclin D1F: 5′-CTGTGCTGCGAAGTGGAAACCAT-3′
R: 5′-TTCATGGCCAGCGGGAAGACCTC-3′25757
VEGFF: 5′-CGAAGTGGTGAAGTTCATGGATG-3′
R: 5′-TTCTGTATCAGTCTTTCCTGGT-3′47060
β-actinF: 5′-GCATGGAGTCCTGTGGCAT-3′
R: 5′-CATGAAGCATTTGCGGTGG-3′32658

[i] Bp, base pair; F, forward; R, reverse; VEGF, vascular endothelial growth factor.

Transfection of β-catenin RNA interference (RNAi)

Since β-catenin is the central player of Wnt2-mediated signaling (9), the influence of β-catenin downregulation in the resveratrol sensitivity of Colo16 cells was evaluated by RNAi transfection according to the manufacturer's protocol (Roche Diagnostics GmbH, Mannheim, Germany). Three RNAi candidate sequences for the β-catenin transcript were transfected into the cells for 24 h at a final concentration of 0.5 nmol/l. Scrambled oligonucleotides (mock RNA; sense 5′-UUCUCCGAACGUGUCACGUTT-3′ and antisense 5′-ACGUGACACGUUCGGAGA-3′) and p53 siRNAs (sense 5′-CUACUUCCUGAAAACAACGdTdT-3′ and antisense 5′-CGUUGUUUUCAGGAAGUAGdTdT-3′) were used as negative and positive controls of transfection efficiency, respectively. The siRNAs were synthesized by Shanghai Genepharma, Co., Ltd., Shanghai, China. Upon ascertaining the efficiency of β-catenin inhibition according to the gray analysis, Colo16 transfectants were further treated with 100 µM resveratrol, and the cellular responses were evaluated by H&E staining, flow cytometry and ICC staining (7).

Results

Resveratrol inhibits the growth of Colo16 cells

Colo16 SCC cells were treated with 0, 50, 75, 100, 125 and 150 µM resveratrol for 72 h. The IC50 value was determined to be 113.79 µM (data not shown); therefore, 100 µM resveratrol was selected to treat Colo16 SCC cells in subsequent experiments. After 36 h of treatment, decreased Ki-67 production and apoptotic phenotypes could be observed in the Colo16 cell population, which became particularly distinct at 48 h. The majority of treated cells died at 72 h (Fig. 1A). Flow cytometry analysis further demonstrated accumulation of S-phase cells and increased apoptotic fraction (16.804%) in resveratrol-treated cells at 48 h (Fig. 1B) and MTT assay showed growth suppression (Fig 1C).

Figure 1.

Effects of resveratrol on Colo16 human cutaneous squamous cell carcinoma cells. (A) Evaluation of the response of Colo16 cells to 100 µM resveratrol by hematoxylin and eosin morphological staining, immunocytochemical staining for Ki-67 and TUNEL apoptotic cell labeling. (B) Flow cytometry fractionation of cell cycle phases and apoptosis in Colo16 cell populations without and with resveratrol treatment for 48 h. (C) MTT results following treatment for 24 or 48 h with various concentrations of resveratrol. TUNEL, terminal deoxynucleotidyl transferase dUTP nick-end labeling.

Resveratrol inhibits Wnt activation

The expression of Wnt2, Wnt5a and four target genes of the classical Wnt signaling pathway in Colo16 cells with and without resveratrol treatment was examined by RT-PCR and western blot analyses. As shown in Fig. 2, constitutive expression of Wnt2, Wnt5a, survivin, VEGF, cyclin D1 and c-Myc was observed in Colo16 cells under normal culture conditions. Upon resveratrol treatment, Wnt2, survivin, cyclin D1, c-Myc and VEGF transcription was downregulated, while the levels of Wnt5a expression were almost unchanged. As presented in Table II, the expression of Axin2, a negative regulator of the Wnt signaling pathway, was upregulated in resveratrol-treated Colo16 cells (10).

Figure 2.

Analyses of Wnt2, Wnt5a, Axin2 and Wnt target gene (survivin, c-Myc, cyclin D1 and VEGF) expression in Colo16 cells without and with 100 µM resveratrol treatment for 48 h by RT-PCR and western blotting. β-actin was used as a quantitative control. Gray density analysis was conducted on the Wnt2, Wnt5a, Axin2 and Wnt target gene data. N, normal culture; R, 100 µM resveratrol treatment; VEGF, vascular endothelial growth factor; RT-PCR, reverse transcription-polymerase chain reaction.

Table II.

Resveratrol-regulated gene expression in Colo16 cells.

Table II.

Resveratrol-regulated gene expression in Colo16 cells.

GeneICCWestern blottingRT-PCR
Wnt2↓―↓
Wnt5a―――
Axin2↑↑↑
Survivin↓↓↓
c-Myc↓↓↓
cyclin D1↓↓↓
VEGF↓↓↓

[i] ICC, immunocytochemical; RT-PCR, reverse transcription-polymerase chain reaction; VEGF, vascular endothelial growth factor.

Enhanced resveratrol sensitivity by β-catenin siRNA transfection

RT-PCR analysis revealed that β-catenin expression was inhibited by siRNA approach. According to the results of gray analysis, the siRNA candidates in the sequences of sense 5′-GCUUUAUUCUCCCAUUGAATT-3′ and antisense 5′-UUCAAUGGGAGAAUAAAGCAG-3′ exhibited a marked inhibitory effect (63%) on β-catenin expression (Fig. 3B), which was accompanied with less frequent β-catenin nuclear translocation in the transfectants (Fig. 3A). Distinct apoptosis (14.896%) appeared much earlier in resveratrol-treated transfectants than in Colo16 cells treated by resveratrol only (Fig. 3A and C). Almost all cells in the Res + RNAi group died at the 48-h time point.

Figure 3.

Influence of β-catenin-specific siRNA in the growth and resveratrol sensitivity of Colo16 cells. (A) β-catenin immunocytochemical examination of the inhibitory effects of a β-catenin-specific siRNA and its combination with 24-h treatment of 100 µM resveratrol on the β-catenin expression of Colo16 cells. Normally cultured cells were used as controls. (B) Reverse transcription-polymerase chain reaction and gray density analysis of β-catenin expression in Colo16 cells under normal culture conditions, or treated with 100 µM resveratrol for 48 h, RNAi or RNAi and 100 µM resveratrol for 24 h. (C) Flow cytometry was performed on β-catenin siRNA transfectants without RNAi and with 100 µM resveratrol treatment at 24 h. Colo16 cells treated with 100 µM resveratrol only were used as the control. N, normal culture; Res, resveratrol; RNAi, RNA interference; siRNA, small interfering RNA.

Discussion

Resveratrol exerts therapeutic effects on different types of human malignancies at a concentration of 100 µM (11–13), while its influence in the growth and survival of human cutaneous SCCs remains obscure. To shed light on this issue, Colo16 cutaneous SCC cells were treated with 100 µM resveratrol in the present study. Decreased Ki-67 production and apoptotic phenotypes in the Colo16 cell population were markedly distinct at 48 h, and the majority of treated cells died at 72 h. Accumulation of S-phase cells and increased apoptotic fraction (16.804%) in resveratrol-treated cells were observed at 48 h. These results suggest that Colo16 is a resveratrol-sensitive human SCC cell line.

Frequent activation of Wnt signaling has been observed in human cutaneous SCC cells (6), but its biological importance in these cells is less known. Therefore, RT-PCR and western blot analyses were performed in the present study to detect the expression of Wnt2, Wnt5a and target genes of the classical Wnt signaling pathway in Colo16 cells. The results suggest that resveratrol can lead Colo16 cells to growth arrest and apoptosis, probably due to inhibition of the classical Wnt signaling pathway and downregulation of certain Wnt target genes that are critical for human SCCs (6,14,15). This notion was further supported by the remarkable upregulation of Axin2 expression in resveratrol-treated Colo16 cells, since Axin2 acts as a negative regulator of the Wnt signaling pathway by promoting glycogen synthase kinase 3β-dependent phosphorylation of β-catenin (16). The unchanged Wnt5a expression in resveratrol-treated Colo16 cells observed in the present study was not unexpected, as Wnt5a mediates non-canonical (i.e. β-catenin-independent) signaling and functions as a negative regulator of Wnt/β-catenin activity (17) or as a tumor-suppressor gene (18).

β-catenin serves a central role in the classical Wnt signaling pathway through nuclear translocation to initiate Wnt target gene transcription (9). To ascertain the importance of Wnt activation in Colo16 cells, β-catenin expression was inhibited by siRNA approach in the present study. The results revealed that β-catenin siRNA treatment by itself failed to cause cell death, suggesting that the suppressed biological activities of Wnt signaling may be compensated by other activated signaling pathways to maintain the survival of Colo16 cells. Furthermore, distinct apoptosis (14.896%) appeared much earlier in resveratrol-treated transfectants than in Colo16 cells treated with resveratrol only. This phenomenon further suggested multiple molecular targeting features of resveratrol in cancer cells (13,19). In this context, resveratrol treatment rather than a signaling-specific strategy may achieve better therapeutic effects on human epidermal SCCs.

Acknowledgements

The present study was supported by grants from the National Natural Science Foundation of China (grant nos. 81450016, 81272786, 81071971, 81072063 and 30971038), Research Fund for PhD supervisors from the National Education Department of China (grant no. 20122105110005), Program Fund for Liaoning Excellent Talents in University (grant no. LJQ2012078) and Program Fund for Liaoning Natural Science Foundation (grant nos. 2013023050 and 2013023040).

References

1 

Kim RH and Armstrong AW: Nonmelanoma skin cancer. Dermatol Clin. 30125–139. (ix)2012. View Article : Google Scholar : PubMed/NCBI

2 

Singh CK, Ndiaye MA and Ahmad N: Resveratrol and cancer: Challenges for clinical translation. Biochim Biophys Acta. 1852:1178–1185. 2015. View Article : Google Scholar : PubMed/NCBI

3 

George J, Singh M, Srivastava AK, Bhui K, Roy P, Chaturvedi PK and Shukla Y: Resveratrol and black tea polyphenol combination synergistically suppress mouse skin tumors growth by inhibition of activated MAPKs and p53. PLoS One. 6:e233952011. View Article : Google Scholar : PubMed/NCBI

4 

Aziz MH, Reagan-Shaw S, Wu J, Longley BJ and Ahmad N: Chemoprevention of skin cancer by grape constituent resveratrol: Relevance to human disease? FASEB J. 19:1193–1195. 2005.PubMed/NCBI

5 

Moore GE, Merrick SB, Woods LK and Arabasz NM: A human squamous cell carcinoma cell line. Cancer Res. 35:2684–2688. 1975.PubMed/NCBI

6 

Li Y, Liu ZL, Zhang KL, Chen XY, Kong QY, Wu ML, Sun Y, Liu J and Li H: Methylation-associated silencing of S100A4 expression in human epidermal cancers. Exp Dermatol. 18:842–848. 2009. View Article : Google Scholar : PubMed/NCBI

7 

Xia SL, Wu ML, Li H, Wang JH, Chen NN, Chen XY, Kong QY, Sun Z and Liu J: CRABP-II- and FABP5-independent responsiveness of human glioblastoma cells to all-trans retinoic acid. Oncotarget. 6:5889–5902. 2015. View Article : Google Scholar : PubMed/NCBI

8 

Liu ZL, Li Y, Kong QY, Zhan C, Wang Q, Chen XY, Sun Y, Wen S, Tu CX, Liu J and Li H: Immunohistochemical profiling of Wnt, NF-kappaB, Stat3 and Notch signaling in human epidermal tumors. J Dermatol Sci. 52:133–136. 2008. View Article : Google Scholar : PubMed/NCBI

9 

Skalka N, Caspi M, Caspi E, Loh YP and Rosin-Arbesfeld R: Carboxypeptidase E: A negative regulator of the canonical Wnt signaling pathway. Oncogene. 32:2836–2847. 2013. View Article : Google Scholar : PubMed/NCBI

10 

Wu ZQ, Brabletz T, Fearon E, Willis AL, Hu CY, Li XY and Weiss SJ: Canonical Wnt suppressor, Axin2, promotes colon carcinoma oncogenic activity. Proc Natl Acad Sci USA. 109:pp. 11312–11317. 2012; View Article : Google Scholar : PubMed/NCBI

11 

Mikuła-Pietrasik J, Sosińska P and Książek K: Resveratrol inhibits ovarian cancer cell adhesion to peritoneal mesothelium in vitro by modulating the production of α5β1 integrins and hyaluronic acid. Gynecol Oncol. 134:624–630. 2014. View Article : Google Scholar : PubMed/NCBI

12 

Wang Q, Li H, Wang XW, Wu DC, Chen XY and Liu J: Resveratrol promotes differentiation and induces Fas-independent apoptosis of human medulloblastoma cells. Neurosci Lett. 351:83–86. 2003. View Article : Google Scholar : PubMed/NCBI

13 

Wen S, Li H, Wu ML, Fan SH, Wang Q, Shu XH, Kong QY, Chen XY and Liu J: Inhibition of NF-κB signaling commits resveratrol-treated medulloblastoma cells to apoptosis without neuronal differentiation. J Neurooncol. 104:169–177. 2011. View Article : Google Scholar : PubMed/NCBI

14 

Klaus A and Birchmeier W: Wnt signalling and its impact on development and cancer. Nat Rev Cancer. 8:387–398. 2008. View Article : Google Scholar : PubMed/NCBI

15 

Malanchi I, Peinado H, Kassen D, Hussenet T, Metzger D, Chambon P, Huber M, Hohl D, Cano A, Birchmeier W and Huelsken J: Cutaneous cancer stem cell maintenance is dependent on beta-catenin signalling. Nature. 452:650–653. 2008. View Article : Google Scholar : PubMed/NCBI

16 

Bernkopf DB, Hadjihannas MV and Behrens J: Negative-feedback regulation of the Wnt pathway by conductin/axin2 involves insensitivity to upstream signalling. J Cell Sci. 128:33–39. 2015. View Article : Google Scholar : PubMed/NCBI

17 

Bisson JA, Mills B, Helt JC Paul, Zwaka TP and Cohen ED: Wnt5a and Wnt11 inhibit the canonical Wnt pathway and promote cardiac progenitor development via the Caspase-dependent degradation of AKT. Dev Biol. 398:80–96. 2015. View Article : Google Scholar : PubMed/NCBI

18 

Abdelmaksoud-Dammak R, Miladi-Abdennadher I, Saadallah-Kallel A, Khabir A, Sellami-Boudawara T, Frikha M, Daoud J and Mokdad-Gargouri R: Downregulation of WIF-1 and Wnt5a in patients with colorectal carcinoma: Clinical significance. Tumour Biol. 35:7975–7982. 2014. View Article : Google Scholar : PubMed/NCBI

19 

Yu LJ, Wu ML, Li H, Chen XY, Wang Q, Sun Y, Kong QY and Liu J: Inhibition of STAT3 expression and signaling in resveratrol-differentiated medulloblastoma cells. Neoplasia. 10:736–744. 2008. View Article : Google Scholar : PubMed/NCBI

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Liu ZL, Li H, Liu J, Wu ML, Chen XY, Liu LH and Wang Q: Inactivated Wnt signaling in resveratrol-treated epidermal squamous cancer cells and its biological implication. Oncol Lett 14: 2239-2243, 2017.
APA
Liu, Z., Li, H., Liu, J., Wu, M., Chen, X., Liu, L., & Wang, Q. (2017). Inactivated Wnt signaling in resveratrol-treated epidermal squamous cancer cells and its biological implication. Oncology Letters, 14, 2239-2243. https://doi.org/10.3892/ol.2017.6458
MLA
Liu, Z., Li, H., Liu, J., Wu, M., Chen, X., Liu, L., Wang, Q."Inactivated Wnt signaling in resveratrol-treated epidermal squamous cancer cells and its biological implication". Oncology Letters 14.2 (2017): 2239-2243.
Chicago
Liu, Z., Li, H., Liu, J., Wu, M., Chen, X., Liu, L., Wang, Q."Inactivated Wnt signaling in resveratrol-treated epidermal squamous cancer cells and its biological implication". Oncology Letters 14, no. 2 (2017): 2239-2243. https://doi.org/10.3892/ol.2017.6458
Copy and paste a formatted citation
x
Spandidos Publications style
Liu ZL, Li H, Liu J, Wu ML, Chen XY, Liu LH and Wang Q: Inactivated Wnt signaling in resveratrol-treated epidermal squamous cancer cells and its biological implication. Oncol Lett 14: 2239-2243, 2017.
APA
Liu, Z., Li, H., Liu, J., Wu, M., Chen, X., Liu, L., & Wang, Q. (2017). Inactivated Wnt signaling in resveratrol-treated epidermal squamous cancer cells and its biological implication. Oncology Letters, 14, 2239-2243. https://doi.org/10.3892/ol.2017.6458
MLA
Liu, Z., Li, H., Liu, J., Wu, M., Chen, X., Liu, L., Wang, Q."Inactivated Wnt signaling in resveratrol-treated epidermal squamous cancer cells and its biological implication". Oncology Letters 14.2 (2017): 2239-2243.
Chicago
Liu, Z., Li, H., Liu, J., Wu, M., Chen, X., Liu, L., Wang, Q."Inactivated Wnt signaling in resveratrol-treated epidermal squamous cancer cells and its biological implication". Oncology Letters 14, no. 2 (2017): 2239-2243. https://doi.org/10.3892/ol.2017.6458
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team